Usually, it takes years of research and testing before a vaccine can be released on the market. Pharmaceutical companies around the world are racing to develop a COVID-19 vaccine and introduce it to the market in the least amount of time possible to stop the COVID-19 pandemic in its tracks.
There are dozens of COVID-19 vaccine candidates at various stages of development globally. Which COVID-19 vaccine is furthest along in development? Which vaccine is the most promising?
Even as drug companies race to release a COVID-19 vaccine, they have pledged to only release products that meet the required safety standards. The need to reassure the public about COVID-19 vaccine safety has become necessary as political pressure grows on pharmaceutical companies to develop a vaccine quickly. There have been safety concerns as politicians try to take credit for COVID-19 vaccine success.
Which COVID-19 vaccine is the most promising?
Moderna and Pfizer are the COVID-19 vaccine candidates furthest along. On Nov. 16, Moderna announced that its COVID-19 vaccine candidate is more than 94 percent effective based on preliminary data analysis from the vaccine’s Phase 3 trial. Moderna CEO Stephane Bancel thinks that the company’s vaccine candidate is a “game-changer.”
Last week, Pfizer announced that its COVID-19 vaccine is more than 90 percent effective based on preliminary analysis of Phase 3 trial data. Pfizer and Moderna have emerged as the frontrunners in the race to bring a COVID-19 vaccine to the market.
Pfizer has teamed up with BioNTech on its COVID-19 vaccine program. Moderna is collaborating with the National Institute of Allergy and Infectious Diseases on its vaccine program. In addition to being effective, Pfizer and Moderna have both said that their vaccine candidates are generally safe.
Which COVID-19 vaccines are in Phase 3?
There are at least 12 COVID-19 vaccine candidates in large-scale Phase 3 trials. In addition to Moderna and Pfizer, the other companies with vaccine candidates in Phase 3 studies include CanSino Biologics, Johnson & Johnson, AstraZeneca, Novavax, and Medicago. Canada-based Medicago is collaborating with GlaxoSmithKline on its COVID-19 vaccine program.